Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAAT3 | P53816 | 1/20 | 0.37 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.37 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.37 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161533 | 1.00 | PLAAT3 (0.37) | PLAAT3PLAAT5PLAAT2PLAAT4HPGD | |
| SCHEMBL7836232 | 0.83 | MEN1 (0.45) | PLAAT3PLAAT5PLAAT2PLAAT4HPGD | |
| SCHEMBL7836234 | 0.83 | MEN1 (0.45) | PLAAT3PLAAT5PLAAT2PLAAT4HPGD | |
| SCHEMBL6153056 | 0.81 | BACE1 (0.40) | PLAAT3PLAAT5PLAAT2PLAAT4HPGD | |
| SCHEMBL6153057 | 0.81 | BACE1 (0.40) | PLAAT3PLAAT5PLAAT2PLAAT4HPGD | |
| SCHEMBL6153618 | 0.80 | CDYL (0.39) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6152350 | 0.79 | HPGD (0.39) | HPGDMAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL6153271 | 0.77 | PLAAT3 (0.34) | PLAAT3PLAAT5PLAAT2PLAAT4HPGD | |
| SCHEMBL6152947 | 0.77 | PLAAT3 (0.34) | PLAAT3PLAAT5PLAAT2PLAAT4HPGD | |
| SCHEMBL11778569 | 0.76 | MAPT (0.45) | HPGDMAPTNPSR1GLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307449-B1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMA (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6653313-B2 | For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders | WARNER-LAMBERT COMPANY LLC | 2003-11-25 | — | — | US | disclosed |
| EP-1307449-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | KAWAMURA MITSUHIRO (US) | 2002-10-31 | — | — | US | disclosed |
| WO-2002012235-A1 | 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161006-A1 | 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | PLAAT3 3652/4885PLAAT5 3156/4885PLAAT2 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.